Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1

Interventions

pembrolizumab 141Nivolumab 117Ipilimumab 69Cyclophosphamide 34Specimen Handling 30Magnetic Resonance Spectroscopy 28trametinib 23fludarabine 22binimetinib 22Interleukin-2 21dabrafenib 19relatlimab 17encorafenib 17Biopsy 17aldesleukin 16CTLA-4 Antigen 16fludarabine phosphate 15cemiplimab 15atezolizumab 15Radiosurgery 15Opdualag 14Radiotherapy 11lifileucel 10lenvatinib 10Blood Specimen Collection 10spartalizumab 8Paclitaxel 8Cisplatin 8Bevacizumab 8cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Hsp90 inhibitor KU757 × 1 year × Clear all
NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
26 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡